Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study

Jeroen F. Vermeulen, Aram S A Van Brussel, Arthur Adams, Willem P Th M Mali, Elsken Van Der Wall, Paul J. Van Diest, Patrick W B Derksen

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery. As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS. Procedure: Mice bearing orthotopically transplanted CD44v6-positive MCF10DCIS DCIS-like tumors and CD44v6-negative MDA-MB-231 control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs. Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging. Antibody accumulation and intratumor distribution were examined. Results: Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection. Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection. Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging. Conclusions: We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.

Original languageEnglish (US)
Pages (from-to)290-298
Number of pages9
JournalMolecular Imaging and Biology
Volume15
Issue number3
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Molecular Imaging
Carcinoma, Intraductal, Noninfiltrating
Optical Imaging
Antibodies
Neoplasms
Immunoglobulin G

Keywords

  • Antibody
  • Breast cancer
  • DCIS
  • IRDye800CW
  • Mouse model
  • NIRF
  • Optical imaging

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Vermeulen, J. F., Van Brussel, A. S. A., Adams, A., Mali, W. P. T. M., Van Der Wall, E., Van Diest, P. J., & Derksen, P. W. B. (2013). Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study. Molecular Imaging and Biology, 15(3), 290-298. https://doi.org/10.1007/s11307-012-0605-8

Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice : A Preclinical Study. / Vermeulen, Jeroen F.; Van Brussel, Aram S A; Adams, Arthur; Mali, Willem P Th M; Van Der Wall, Elsken; Van Diest, Paul J.; Derksen, Patrick W B.

In: Molecular Imaging and Biology, Vol. 15, No. 3, 06.2013, p. 290-298.

Research output: Contribution to journalArticle

Vermeulen, JF, Van Brussel, ASA, Adams, A, Mali, WPTM, Van Der Wall, E, Van Diest, PJ & Derksen, PWB 2013, 'Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study', Molecular Imaging and Biology, vol. 15, no. 3, pp. 290-298. https://doi.org/10.1007/s11307-012-0605-8
Vermeulen, Jeroen F. ; Van Brussel, Aram S A ; Adams, Arthur ; Mali, Willem P Th M ; Van Der Wall, Elsken ; Van Diest, Paul J. ; Derksen, Patrick W B. / Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice : A Preclinical Study. In: Molecular Imaging and Biology. 2013 ; Vol. 15, No. 3. pp. 290-298.
@article{ec99f8fb5b1b464089159b559b44ba7a,
title = "Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study",
abstract = "Purpose: The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery. As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS. Procedure: Mice bearing orthotopically transplanted CD44v6-positive MCF10DCIS DCIS-like tumors and CD44v6-negative MDA-MB-231 control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs. Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging. Antibody accumulation and intratumor distribution were examined. Results: Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection. Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection. Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging. Conclusions: We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.",
keywords = "Antibody, Breast cancer, DCIS, IRDye800CW, Mouse model, NIRF, Optical imaging",
author = "Vermeulen, {Jeroen F.} and {Van Brussel}, {Aram S A} and Arthur Adams and Mali, {Willem P Th M} and {Van Der Wall}, Elsken and {Van Diest}, {Paul J.} and Derksen, {Patrick W B}",
year = "2013",
month = "6",
doi = "10.1007/s11307-012-0605-8",
language = "English (US)",
volume = "15",
pages = "290--298",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice

T2 - A Preclinical Study

AU - Vermeulen, Jeroen F.

AU - Van Brussel, Aram S A

AU - Adams, Arthur

AU - Mali, Willem P Th M

AU - Van Der Wall, Elsken

AU - Van Diest, Paul J.

AU - Derksen, Patrick W B

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery. As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS. Procedure: Mice bearing orthotopically transplanted CD44v6-positive MCF10DCIS DCIS-like tumors and CD44v6-negative MDA-MB-231 control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs. Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging. Antibody accumulation and intratumor distribution were examined. Results: Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection. Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection. Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging. Conclusions: We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.

AB - Purpose: The purpose of this study was to develop a molecular imaging technique using tracers specific for ductal carcinoma in situ (DCIS) to improve visualization and localization of DCIS during surgery. As CD44v6 is frequently expressed in DCIS, we used near-infrared fluorescently labeled CD44v6-targeting antibodies for detection of DCIS. Procedure: Mice bearing orthotopically transplanted CD44v6-positive MCF10DCIS DCIS-like tumors and CD44v6-negative MDA-MB-231 control tumors were intravenously injected with IRDye800CW conjugated to CD44v6-specific antibodies or control IgGs. Noninvasive imaging was performed for 8 days postinjection, followed by intraoperative imaging. Antibody accumulation and intratumor distribution were examined. Results: Maximum accumulation of CD44v6-specific antibodies was obtained 24 h postinjection. Maximum tumor-to-background ratio for MCF10DCIS tumors was 4.5 ± 0.2, compared to 1.4 ± 0.1 (control tumors, p = 0.006), and 1.7 ± 0.1 (control IgG, p = 0.014), for 8 days postinjection. Ex vivo, tumor-to-background ratios were comparable to those obtained by intraoperative imaging. Conclusions: We show the applicability of noninvasive and intraoperative optical imaging of DCIS-like lesions in vivo using CD44v6-specific antibodies.

KW - Antibody

KW - Breast cancer

KW - DCIS

KW - IRDye800CW

KW - Mouse model

KW - NIRF

KW - Optical imaging

UR - http://www.scopus.com/inward/record.url?scp=84877784814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877784814&partnerID=8YFLogxK

U2 - 10.1007/s11307-012-0605-8

DO - 10.1007/s11307-012-0605-8

M3 - Article

C2 - 23184608

AN - SCOPUS:84877784814

VL - 15

SP - 290

EP - 298

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 3

ER -